Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

News Conference News ACC 2024

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

Shelley Wood

April 07, 2024

News Conference News ACC 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

L.A. McKeown

April 06, 2024

News Conference News ESC 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

L.A. McKeown

September 01, 2023

News Daily News

New AHA/ACC Performance and Quality Metrics for Coronary Revascularization

Michael O'Riordan

July 28, 2023

News Daily News

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Michael O'Riordan

July 20, 2023

News Daily News

Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death

Michael O'Riordan

July 07, 2023

News Daily News

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Michael O'Riordan

November 29, 2022

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Shelley Wood

July 25, 2022

News Daily News

Mediterranean Diet Bests Low Fat for Secondary Prevention: CORDIOPREV

Michael O'Riordan

May 09, 2022

News Daily News

Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care

Shelley Wood

May 27, 2021

News Conference News ESC 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Michael O'Riordan

August 28, 2020

News Conference News AHA 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Yael L. Maxwell

November 21, 2019

News Daily News

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Michael O'Riordan

April 22, 2019

News Conference News ESC 2018

Sobering News From Europe: CVD Risk Factors Are on the Rise or Holding Firm

Todd Neale

August 27, 2018

News Conference News

CANVAS Analysis Provides Heart Failure Reassurances for Canagliflozin

Michael O'Riordan

March 16, 2018

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

AHA Scientific Statement Highlights Sex Disparities in CV Risk Among Diabetic Patients

L.A. McKeown

December 09, 2015

News Daily News

Early QOL Advantage of CABG Over PCI for Diabetic Patients Disappears After 2 Years

L.A. McKeown

October 15, 2013

News Daily News

Women vs. Men in BARI 2D: Equal Survival but Worse Quality of Life

March 09, 2013

News Daily News

BARI 2D: Prompt Revascularization Improves Angina Symptoms in Diabetics

L.A. McKeown

April 01, 2011

Advertisement

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

New AHA/ACC Performance and Quality Metrics for Coronary Revascularization

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Mediterranean Diet Bests Low Fat for Secondary Prevention: CORDIOPREV

Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Sobering News From Europe: CVD Risk Factors Are on the Rise or Holding Firm

CANVAS Analysis Provides Heart Failure Reassurances for Canagliflozin

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

AHA Scientific Statement Highlights Sex Disparities in CV Risk Among Diabetic Patients

Early QOL Advantage of CABG Over PCI for Diabetic Patients Disappears After 2 Years

Women vs. Men in BARI 2D: Equal Survival but Worse Quality of Life

BARI 2D: Prompt Revascularization Improves Angina Symptoms in Diabetics

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content